Bristol-Myers Squibb

BMYleader

Bristol-Myers Squibb is a global biopharmaceutical company with leading franchises in oncology and cardiovascular medicine. Eliquis is the world's best-selling oral anticoagulant and Opdivo is a top-selling cancer immunotherapy.

⇄ Compare

Productos e Ingresos

Participación de Ingresos por Producto

Desglose de Ingresos ($45.0B)

Datos estáticos (cargando finanzas en tiempo real…)

Oncology (42%)

Cardiovascular (33%)

Immunology (15%)

Other (10%)

Composición de segmentos y clientes principales

Detalles del producto

Eliquis30%

Blood thinner for stroke prevention in atrial fibrillation

Opdivo25%

Immuno-oncology checkpoint inhibitor for multiple cancer types

Revlimid15%

Treatment for multiple myeloma and other blood cancers

Other Specialty30%

Cardiovascular, immunology, and fibrosis therapeutics pipeline

Relaciones en la Cadena de Suministro

Competidores

Johnson & Johnson

Oncology, immunology drugs

Impacto: Major pharma competitor

Clientes Clave

UnitedHealth Group

Formulary drug placements

Impacto: $3B+ annually

The Cigna Group

Drug coverage via Express Scripts

Impacto: $2B+ annually

Contexto macro y de mercado

헬스케어Noticias del sector

메디케어 수가 압박 vs AI 진단 효율화 — 선별적 접근 필요

미국 헬스케어 지출 (2026E)

$4.8T

AI 진단 정확도 개선

+23% vs 기존

UNH 의료손해율

87.3%

약가 협상 대상 의약품

20종 (IRA)

Próximos catalizadores

◆CMS 메디케어 최종 수가 발표 (2026.Q2)◆UNH/HUM/CVS Q1 실적 (2026.04)◆IRA 약가 협상 2차 품목 공개

Últimas noticias

Cargando noticias...

Análisis IA

Haz clic en "Obtener Análisis IA" para un análisis de cadena de suministro de Bristol-Myers Squibb impulsado por IA.

Información de la Empresa

Sede Central

New York, New York, USA

Fundación

1887

Empleados

34,000+

Sitio Web

bms.com

Estado del sector — 헬스케어

Noticias del sector